Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to check how well a specific liver cancer treatment called transarterial radioembolization (TARE) is working. TARE is used to treat a common type of liver cancer known as hepatocellular carcinoma (HCC). Right now, doctors usually use CT or MRI scans to see if the treatment is working, but these scans can sometimes be unclear for several months after treatment. This delay can make it harder to decide if more treatment is needed or if a patient can move forward with a liver transplant. This study is testing a special type of ultrasound called contrast-enhanced ultrasound (CEUS) that might give clearer and earlier answers about how the cancer is responding to TARE.
The trial plans to include about 30 patients, aged 65 to 74, who are scheduled to receive TARE for the first time for their liver cancer. Participants will have CEUS exams done shortly after their usual CT or MRI scans, about 1-2 months and again 4-6 months after treatment. The study will take place across six hospitals within the Jefferson Health Enterprise, and patients will be carefully informed about the study before deciding whether to join. If you or a loved one fits this age range and is about to start TARE for liver cancer, this trial might offer an opportunity to help improve how doctors monitor treatment success.
Gender
ALL
Eligibility criteria
About Thomas Jefferson University
Thomas Jefferson University is a distinguished academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to advancing healthcare through research and education. As a clinical trial sponsor, the university leverages its extensive resources and interdisciplinary expertise to conduct innovative research aimed at improving patient outcomes. With a focus on translational medicine, Thomas Jefferson University collaborates with various stakeholders, including healthcare professionals, industry partners, and regulatory agencies, to ensure the highest standards of scientific rigor and ethical conduct in its clinical trials. The institution is dedicated to fostering a culture of excellence in research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
John Eisenbrey, PhD
Principal Investigator
Thomas Jefferson University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported